Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080394 | 0.86 | MAPK1 (0.33) | MAPK1CHRNEDPP4 | |
| SCHEMBL18081754 | 0.83 | CHRNE (0.35) | CHRNEHDAC1 | |
| SCHEMBL16631910 | 0.82 | MEN1 (0.31) | MAPK1HPGD | |
| SCHEMBL16631913 | 0.79 | CYP19A1 (0.52) | HDAC1 | |
| SCHEMBL16631915 | 0.77 | KCNMA1 (0.55) | CHRNEHPGD | |
| SCHEMBL16631906 | 0.77 | CYP19A1 (0.38) | — | |
| SCHEMBL16631917 | 0.72 | DPP4 (0.35) | CHRNEDPP4HDAC1 | |
| SCHEMBL20215653 | 0.71 | DAO (0.46) | MAPK1DAO | |
| SCHEMBL35260 | 0.71 | SMN1; SMN2 (0.42) | MAPK1DAOHPGD | |
| SCHEMBL18081774 | 0.71 | AMY1A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | MAPK1 4185/4885CHRNE 4102/4885DPP4 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.